Physician profile
William Mark Handy
NPI 1124017744
$2,198.75
in general payments reported to CMS, 2019-2025
31 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $14.87 · 2021: $16.31 · 2023: $137 · 2024: $672 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $351.09 | 2020-2025 | Zepbound, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $193.11 | 2019-2024 | Airsupra, Farxiga |
| Abbvie INC. | $188.82 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.30 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $155.42 | 2019-2025 | |
| Esperion Therapeutics, INC. | $145.44 | 2024-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.36 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $108.64 | 2019-2025 | Wegovy |
| Alkermes, INC. | $86.71 | 2024-2025 | Lybalvi |
| Axsome Therapeutics, INC. | $73.92 | 2024-2025 | Auvelity |
| Abbott Laboratories | $73.39 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $66.48 | 2019-2025 | Evenity |
| E.R. Squibb & Sons, L.L.C. | $51.42 | 2023-2024 | Camzyos, Eliquis |
| Sumitomo Pharma America, INC. | $48.45 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.55 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.30 | 2025 | |
| Phathom Pharmaceuticals, INC. | $30.42 | 2025 | Voquezna |
| Viiv Healthcare Company | $29.11 | 2025 | Apretude |
| Glaxosmithkline, LLC. | $27.01 | 2019-2025 | Trelegy Ellipta |
| Inspire Medical Systems, INC. | $24.98 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $24.49 | 2019 | |
| Exact Sciences Corporation | $22.91 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $20.19 | 2024 | Rexulti |
| Ardelyx, INC. | $18.50 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.97 | 2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $16.03 | 2024 | Zoryve |
| Lundbeck LLC | $15.66 | 2025 | Rexulti |
| Medtronic, INC. | $14.60 | 2024 | Intellis Adaptivestim |
| Antares Pharma, INC. | $14.42 | 2019 | |
| Circassia INC. | $11.99 | 2019 | |
| Advanced Oxygen Therapy INC. | $9.07 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Handy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.